Drug evaluation: Bevirimat - HIV Gag protein and viral maturation inhibitor

Zelalem Temesgen, Judith E. Feinberg

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

Original languageEnglish (US)
Pages (from-to)759-765
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume7
Issue number8
StatePublished - Aug 2006

Fingerprint

Human Immunodeficiency Virus Proteins
gag Gene Products
Phase II Clinical Trials
Drug Evaluation
HIV Infections
Pharmaceutical Preparations
bevirimat

ASJC Scopus subject areas

  • Pharmacology

Cite this

Drug evaluation : Bevirimat - HIV Gag protein and viral maturation inhibitor. / Temesgen, Zelalem; Feinberg, Judith E.

In: Current Opinion in Investigational Drugs, Vol. 7, No. 8, 08.2006, p. 759-765.

Research output: Contribution to journalArticle

@article{4b01f45e61144ed6ad633cbc60fc4bee,
title = "Drug evaluation: Bevirimat - HIV Gag protein and viral maturation inhibitor",
abstract = "Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.",
author = "Zelalem Temesgen and Feinberg, {Judith E.}",
year = "2006",
month = "8",
language = "English (US)",
volume = "7",
pages = "759--765",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Drug evaluation

T2 - Bevirimat - HIV Gag protein and viral maturation inhibitor

AU - Temesgen, Zelalem

AU - Feinberg, Judith E.

PY - 2006/8

Y1 - 2006/8

N2 - Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

AB - Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

UR - http://www.scopus.com/inward/record.url?scp=33747601418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747601418&partnerID=8YFLogxK

M3 - Article

C2 - 16955688

AN - SCOPUS:33747601418

VL - 7

SP - 759

EP - 765

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 8

ER -